| Literature DB >> 24527230 |
J Carlos Pastor1, Itziar Fernández2, Rosa M Coco3, María R Sanabria4, Enrique Rodríguez de la Rúa5, Rosa M Piñon6, Vicente Martinez7, Anna Sala-Puigdollers8, José M Gallardo9, Sara Velilla10.
Abstract
Purpose. To analyse variations in the anatomical and functional outcomes and in proliferative vitreoretinopathy (PVR) rate of a prospective multicentric study that was primarily designed for identification of clinical risk factors for PVR. Methods. 1,046 retinal detachment (RD) cases were analysed. Cases were divided into two series based upon variation in PVR rate determined by logistic regression analysis. Series 1 (S1) included RD treated during 2004-2005 (n = 481) and Series 2 (S2) during 2006-2008 (n = 565). Pre-, intra-, and postoperative characteristics were recorded. Results. There were few differences in the preoperative characteristics. S2 had more vitrectomies and scleral bands and fewer explants and associated cataract extractions than S1. Anatomic reattachment improved from 87.9% to 92.9% in S1 and S2, respectively, (P = 0.006). Visual acuity at 3 months ≥20/40 increased from 36.5% of S1 to 44.2% in S2 (P = 0.049). PVR rate diminished from 14.1% in S1 to 8.1% in S2 (P = 0.002). Centres with higher rates of PVR in S1 showed the greatest reductions in S2. Conclusion. An improvement in anatomical and functional outcome and PVR rate occurred in participating centres cannot be attributed to the learning curve of surgeons. We speculated that it could be an effect of their participation in the study.Entities:
Year: 2012 PMID: 24527230 PMCID: PMC3912585 DOI: 10.5402/2012/206385
Source DB: PubMed Journal: ISRN Ophthalmol ISSN: 2090-5688
Preoperative characteristics.
| Characteristic | S1 | S2 |
| ||
|---|---|---|---|---|---|
| 2004-2005 | 2006–2008 | ||||
|
| 95% CI |
| 95% CI | ||
| Previous PVR | 230 (47.8%) | 43.4%–52.3% | 295 (52.2%) | 48.1%–56.3% | |
| Retinal break | 0.062 | ||||
| Tear | 348 (72.5%) | 68.5%–76.5% | 391 (69.3%) | 65.5%–73.1% | |
| Hole | 86 (17.9%) | 14.5%–21.3% | 137 (24.3%) | 20.8%–27.8% | |
| Dialysis | 6 (1.3%) | 0.3%–2.2% | 6 (1.1%) | 0.2%–1.9% | |
| Giant tear | 20 (4.2%) | 2.4%–6% | 16 (2.8%) | 1.5%–4.2% | |
| Not visible | 20 (4.2%) | 2.4%–6% | 14 (2.5%) | 1.2%–3.8% | |
| Type of break | 0.264 | ||||
| Unique | 232 (50.2%) | 45.7%–54.8% | 293 (53.7%) | 49.5%–57.8% | |
| Multiple | 204 (44.2%) | 39.6%–48.7% | 228 (41.8%) | 37.6%–45.9% | |
| Posterior | 6 (1.3%) | 0.3%–2.3% | 11 (2%) | 0.8%–3.2% | |
| Not visible | 20 (4.3%) | 2.5%–6.2% | 14 (2.6%) | 1.2%–3.9% | |
| Size of breaks (clock hours) | 0.242 | ||||
| 0-1 | 318 (66.9%) | 62.7%–71.2% | 355 (64.2%) | 60.2%–68.2% | |
| 2-3 | 112 (23.6%) | 19.8%–27.4% | 153 (27.7%) | 23.9%–31.4% | |
| >3 | 25 (5.3%) | 3.3%–7.3% | 31 (5.6%) | 3.7%–7.5% | |
| Not visible | 20 (4.2%) | 2.4%–6% | 14 (2.5%) | 1.2%–3.8% | |
| Vitreous hemorrhage | 43 (9%) | 6.4%–11.6% | 81 (14.6%) | 11.7%–17.6% | 0.006 |
| Extension RD (quadrants) | 0.432 | ||||
| 0-1 | 80 (16.7%) | 13.4%–20% | 108 (19.3%) | 16%–22.5% | |
| 2-3 | 341 (71.2%) | 67.1%–75.2% | 395 (70.4%) | 66.6%–74.2% | |
| 4 | 58 (12.1%) | 9.2%–15% | 58 (10.3%) | 7.8%–12.9% | |
| Macula-on | 158 (33.1%) | 28.9%–37.3% | 223 (39.7%) | 35.6%–43.7% | 0.029 |
| Choroidal detachment | 3 (0.6%) | 0%–1.3% | 11 (2%) | 0.8%–3.1% | 0.062 |
| Previous uveitis | 25 (5.2%) | 3.2%–7.2% | 58 (10.4%) | 7.9%–12.9% | 0.002 |
| Previous surgery for RD | 60 (12.6%) | 9.6%–15.5% | 50 (8.9%) | 6.6%–11.3% | 0.062 |
| Previous PPV | 28 (5.9%) | 0%–11.9% | 30 (5.4%) | 0%–11.8% | 0.120 |
| Previous scleral surgery | 37 (7.7%) | 0.9%–14.6% | 19 (3.4%) | 0%–8.5% | 0.017 |
| Aphakia | 161 (33.5%) | 29.3%–37.8% | 221 (39.2%) | 35.2%–43.2% | 0.062 |
| PVD | 241 (50.1%) | 45.6%–54.6% | 256 (45.4%) | 41.3%–49.5% | 0.276 |
| Myopia | 187 (50.1%) | 45.1%–55.2% | 244 (60.5%) | 55.8%–65.3% | 0.012 |
| Ocular trauma | 13 (2.7%) | 1.3%–4.2% | 21 (3.7%) | 2.2%–5.3% | 0.357 |
| Previous ocular surgeries other than RD | 198 (41.2%) | 36.8%–45.6% | 263 (46.6%) | 42.5%–50.7% | 0.080 |
| RD in fellow eye | 38 (7.9%) | 5.5%–10.4% | 44 (7.8%) | 5.6%–10% | 0.945 |
| PVR in fellow eye | 39 (8.4%) | 5.9%–10.9% | 18 (3.2%) | 1.8%–4.7% | <0.001 |
| Previous VA | 0.051 | ||||
| <20/100 | 305 (65%) | 60.7%–69.3% | 325 (57.6%) | 53.5%–61.7% | |
| 20/100–20/40 | 59 (12.6%) | 9.6%–15.6% | 83 (14.7%) | 11.8%–17.7% | |
| ≥20/40 | 105 (22.4%) | 18.7%–26.2% | 156 (27.7%) | 24%–31.4% | |
| DM | 33 (7.1%) | 4.8%–9.4% | 52 (9.5%) | 7%–11.9% | 0.170 |
| RD family history | 15 (4.4%) | 2.2%–6.5% | 33 (7.6%) | 5.1%–10.1% | 0.075 |
| PVR family history | 2 (0.6%) | 0%–1.5% | 9 (2.2%) | 0.8%–3.6% | 0.123 |
N (%): number and percent of proliferative vitreo-retinopathy (PVR) cases; CI: confidence interval; macula-on: retinal detachment with macula attached; PPV: pars plana vitrectomy; PVD: posterior vitreous detachment; myopia: negative refractive error of any value; VA: visual acuity measured with Snellen test with pinhole if necessary; DM: diabetes mellitus.
Intraoperative characteristics.
| Characteristics | S1 | S2 |
| ||
|---|---|---|---|---|---|
| 2004-2005 | 2006–2008 | ||||
|
| 95% CI |
| 95% CI | ||
| PPV | 385 (80%) | 76.5%–83.6% | 446 (79.1%) | 75.7%–82.4% | 0.660 |
| Scleral band | 243 (50.6%) | 46.2%–55.1% | 346 (61.3%) | 57.3%–65.4% | <0.001 |
| PPV associated with band | 171 (44.4%) | 39.5%–49.4% | 266 (59.6%) | 55.1%–64.2% | <0.001 |
| Explant | 55 (11.6%) | 8.7%–14.5% | 39 (7%) | 4.9%–9.1% | 0.010 |
| Retinopexy (cryo) | 16 (3.4%) | 1.8%–5.1% | 28 (5.1%) | 3.2%–6.9% | 0.205 |
| Cryotherapy (clock hours) | 0.326 | ||||
| 1 | 92 (22%) | 18%–26% | 115 (21%) | 17.6%–24.4% | |
| 2 | 42 (10%) | 7.1%–12.9% | 65 (11.9%) | 9.2%–14.6% | |
| >2 | 16 (3.8%) | 2%–5.7% | 33 (6%) | 4%–8% | |
| No | 269 (64.2%) | 59.6%–68.8% | 335 (61.1%) | 57.1%–65.2% | |
| External drainage | 55 (11.6%) | 8.7%–14.4% | 63 (11.3%) | 8.6%–13.9% | 0.878 |
| Tamponade agent | 0.039 | ||||
| Air | 47 (9.9%) | 7.2%–12.5% | 31 (5.5%) | 3.6%–7.4% | |
| SF6 | 187 (39.2%) | 34.8%–43.6% | 226 (40.4%) | 36.3%–44.4% | |
| C3F8 | 191 (40%) | 35.6%–44.4% | 219 (39.1%) | 35.1%–43.1% | |
| Silicone oil | 22 (4.6%) | 2.7%–6.5% | 37 (6.6%) | 4.5%–8.7% | |
| No | 30 (6.3%) | 4.1%–8.5% | 48 (8.6%) | 6.3%–10.9% | |
| Laser (extension in clock hours) | <0.001 | ||||
| 0–2 | 284 (60%) | 55.6%–64.5% | 244 (43.6%) | 39.5%–47.7% | |
| 3–5 | 86 (18.2%) | 14.7%–21.7% | 114 (20.4%) | 17.1%–23.7% | |
| 6–8 | 35 (7.4%) | 5.1%–9.8% | 48 (8.6%) | 6.3%–10.9% | |
| ≥9 | 68 (14.4%) | 11.2%–17.6% | 154 (27.5%) | 23.8%–31.2% | |
| PFCL | 310 (65.1%) | 60.8%–69.4% | 376 (66.9%) | 63%–70.8% | 0.543 |
| Retinotomy | 28 (5.9%) | 3.8%–8% | 38 (6.7%) | 4.7%–8.8% | 0.561 |
| Retinectomy | 8 (1.7%) | 0.5%–2.9% | 3 (0.5%) | 0%–1.2% | 0.071 |
| Choroidal hemorrhage | 6 (1.3%) | 0.3%–2.3% | 13 (2.3%) | 1.1%–3.6% | 0.212 |
| Intravitreal hemorrhage | 18 (3.8%) | 2.1%–5.5% | 26 (4.6%) | 2.9%–6.4% | 0.518 |
| Cataract extraction associated | 60 (12.6%) | 9.6%–15.6% | 41 (7.3%) | 5.2%–9.5% | 0.004 |
| IOL | 49 (10.3%) | 7.6%–13.1% | 33 (5.9%) | 3.9%–7.8% | 0.009 |
N (%): number and percent of proliferative vitreo-retinopathy cases; CI: confidence interval; PPV: pars plana vitrectomy; PFCL: perfluorocarbon liquid intraoperative use; IOL: intraocular lens implantation during surgery.
Postoperative characteristics.
| S1 | S2 |
| |||
|---|---|---|---|---|---|
| 2004-2005 | 2006–2008 | ||||
|
| 95% CI |
| 95% CI | ||
| Uveitis* | 324 (67.8%) | 63.6%–72% | 379 (67.8%) | 63.9%–71.7% | 0.972 |
| Retina reattachment rate | 423 (87.9%) | 85%–90.9% | 525 (92.9%) | 90.8%–95% | 0.006 |
| PVR rate | 68 (14.1%) | 11%–17.3% | 46 (8.1%) | 5.9%–10.4% | 0.002 |
| Choroidal detachment† | 4 (0.8%) | 0%–1.7% | 17 (3%) | 1.6%–4.5% | 0.012 |
| Postoperative VA | 0.049 | ||||
| <20/100 | 109 (25.2%) | 21.1%–29.3% | 122 (22.6%) | 19.1%–26.2% | |
| 20/100–20/40 | 167 (38.6%) | 34%–43.2% | 179 (33.3%) | 29.3%–37.3% | |
| ≥20/40 | 158 (36.5%) | 32%–41% | 238 (44.2%) | 40%–48.4% | |
N (%): number and percent of proliferative vitreo-retinopathy (PVR) cases; CI: confidence interval; VA: best visual acuity corrected at the end of followup (Snellen charts); *during the first month of followup; †during the first 24 h after surgery.
PVR rate according to three groups of centers.
| Centers ( | Patients per center | PVR rate |
| |||
|---|---|---|---|---|---|---|
| S1 | S2 | |||||
| 2004-2005 | 2006–2008 | |||||
|
| 95% CI |
| 95% CI | |||
| G1 (8) | 60 ± 31 | 10 (4.9%) | 1.9%–7.9% | 17 (6.1%) | 3.3%–8.9% | 0.956 |
| G2 (3) | 67.33 ± 33 | 13 (15.9%) | 7.9%–23.8% | 7 (5.8%) | 1.6%–10% | 0.043 |
| G3 (6) | 60.5 ± 58 | 45 (23%) | 17.1%–28.8% | 22 (13.2%) | 8%–18.3% | 0.041 |
PVR: proliferative vitreo-retinopathy; N (%): number and percent of PVR cases; CI: confidence interval; G1: <9% final PVR rate; G2: 9–13% final PVR rate; G3: ≥13 % final PVR rate.